secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001558370-24-008337
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharma Q1 net loss narrows to $6.5M; signs $7.5M debt term sheet to replace toxic debt
--------------------------------------------------------------------------------

- Net loss improved 41% YoY to $6.5M, from $11.0M; R&D spend down to $1.7M.
- Cash and equivalents $1.3M as of March 31, 2024; additional $3.3M from equity post-quarter.
- Signed non-binding term sheet for $7.5M debt to replace toxic debt, with potential total up to $30M.
- Plans to file NDA for NRX-101 in bipolar depression with akathisia risk and for IV ketamine (HTX-100) by July 2024.
- Hope Therapeutics spinout planned; term sheets received from anchor investors for $60M investment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000155837024008337/0001558370-24-008337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000155837024008337/nrxp-20240514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer